ERBB2 and cancer: Ujvira® (ZRC-3256; Zydus Lifesciences, India), a biosimilar version, could offer a more affordable alternative, although real-world experience with it is still limited.<h4>Methods</h4>This retrospective, single-center study evaluated the efficacy and safety of Ujvira® in patients with HER2-positive MBC treated at a tertiary cancer center in India.